You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
We do not review or control the content on non-Medtronic sites, and we are not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations, except those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.
Click “OK” to confirm you are a Healthcare Professional.
This map shows locations of centers offering advanced therapies for Bladder and/or Bowel Control (including Sacral Neuromodulation).
A: Research suggests that bladder and bowel control problems may be caused by miscommunication between the brain and the sacral nerves that are responsible for controlling bladder and bowel function1,2,3.
A. Yes, the evaluation phase is reversible: the stimulation can be switched off at any time and the electrodes removed permanently, if necessary.
A: In addition to risks related to surgery, complications can include pain at the implant site, new pain, infection, lead (thin wire) movement/migration, device problems, undesirable changes in urinary or bowel function, and uncomfortable stimulation (sometimes described as a jolting or shocking feeling). Talk to your doctor about ways to minimize these risks.
A: The life of a device is impacted by many things, including device settings, placement, and other factors. Under expected therapy settings the InterStim™ Micro device can last up to 15 years and the InterStim X™ device can last around 10 years.†
A: You can try it before you decide, and it's reversible if you change your mind later. For bladder and bowel control, the InterStim™ systems deliver sacral neuromodulation (SNM) therapy that has been shown to be more effective than medications for overactive bladder (OAB)4,‡. And unlike botox injections, this therapy doesn’t potentially require self-catheterization or repeated injections within 12 months5.
A: You can have a full-body§ MRI scan if certain conditions are met. Your clinician can provide more details about these conditions, as well as safety information.
A: Since its approval in 1997 for overactive bladder and 2011 for fecal incontinence, the InterStim™ system has been used to treat these problems in more than 400,000 patients worldwide6.
A. Normally, you are not limited in your activities. You should, however, avoid activities that involve bending, twisting, jumping, or stretching abruptly, excessively or repetitively, especially immediately after surgery. These movements could damage the implanted electrode, displace it or damage the neuromodulator implanted. Contact your doctor if you have any concerns or questions about these or other activities.
† Under expected therapy settings and telemetry use
‡ Anticholinergic/antimuscarinic medication.
§ Under certain conditions; see approved labeling for details. Patients with InterStim™ SureScan™ MRI leads only.
Patton V, Wiklendt L, Arkwright JW, et al. The effect of sacral nerve stimulation on distal colonic motility in patients with fecal incontinence. Br J Surg. 2013;100(7):959–968.
Leng WW, Morrisroe SN. Sacral nerve stimulation for the overactive bladder. Urol Clin N Am. 2006;33:491–501.
Chancellor MB, Chartier-Kastler EJ. Principles of sacral nerve stimulation (SNS) for the treatment of bladder and urethral sphincter dysfunctions. Neuromod. 2000;3(1):15–26.
Siegel S, Noblett K, Mangel J, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim™ therapy compared to standard medical therapy at six months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2015;34:224–230.
Chohan N, Hilton P, Brown K, Dixon L. Efficacy and duration of response to botulinum neurotoxin A (onabotulinumA) as a treatment for detrusor overactivity in women. Int Urogynecol J Pelvic Floor Dysfunct. 2015;26(11):1605-1612.
InterStim Implant Numbers, version 2.0, July-2023
The information presented on this website is for information purposes only. It is not intended to replace a consultation with a healthcare professional.